BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 18756260)

  • 1. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease.
    Mizuno Y; Jacob RF; Mason RP
    Am J Hypertens; 2008 Oct; 21(10):1076-85. PubMed ID: 18756260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
    Weir MR
    J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
    Morimoto S; Maki K; Aota Y; Sakuma T; Iwasaka T
    Hypertens Res; 2008 Aug; 31(8):1603-10. PubMed ID: 18971536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
    Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive drugs and fibrinolytic function.
    Fogari R; Zoppi A
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of cardiovascular risk with RAS inhibitor/CCB combination therapy.
    Dahlöf B
    J Hum Hypertens; 2009 Feb; 23(2):77-85. PubMed ID: 18685606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension.
    White WB
    Blood Press Monit; 2008 Apr; 13(2):123-9. PubMed ID: 18347448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.
    Roberts ME; Epstein BJ
    J Cardiovasc Nurs; 2009; 24(5):380-9. PubMed ID: 19707098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus.
    Reboldi G; Gentile G; Angeli F; Verdecchia P
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1349-61. PubMed ID: 19900018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
    Verdecchia P; Angeli F; Cavallini C; Gattobigio R; Gentile G; Staessen JA; Reboldi G
    Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin receptor blockade in the challenging era of systolic hypertension.
    Stergiou GS
    J Hum Hypertens; 2004 Dec; 18(12):837-47. PubMed ID: 15318161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K; Miller NH
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in endothelium-derived hyperpolarizing factor in hypertension and ageing: response to chronic treatment with renin-angiotensin system inhibitors.
    Goto K; Fujii K; Kansui Y; Iida M
    Clin Exp Pharmacol Physiol; 2004 Sep; 31(9):650-5. PubMed ID: 15479174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT(1)-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension.
    Swales P; Williams B
    J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):79-89. PubMed ID: 12228847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The renin system: is direct renin inhibition different from blockade at the AT1 receptor or the ACE step?
    Hollenberg NK
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S7-13. PubMed ID: 17401314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the renin--angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function.
    Neutel JM
    J Hum Hypertens; 2004 Sep; 18(9):599-606. PubMed ID: 15190263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
    Karalliedde J; Viberti G
    J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin inhibition: what are the clinical perspectives?
    Hollenberg NK
    Semin Nephrol; 2007 Sep; 27(5):511-8. PubMed ID: 17868787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.